What is Wedbush’s Forecast for CMPX FY2025 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities research analysts at Wedbush upped their FY2025 earnings per share estimates for Compass Therapeutics in a research note issued on Wednesday, November 5th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.40) for the year, up from their previous forecast of ($0.55). The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.12) EPS and FY2027 earnings at $0.37 EPS.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06.

Other analysts have also recently issued reports about the stock. Lifesci Capital started coverage on shares of Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 price objective for the company. Compass Point set a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, October 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research report on Wednesday, November 5th. Finally, Guggenheim boosted their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.90.

Compass Therapeutics Stock Up 8.2%

Shares of Compass Therapeutics stock opened at $4.63 on Monday. Compass Therapeutics has a 12-month low of $1.27 and a 12-month high of $4.86. The stock has a 50 day moving average price of $3.82 and a two-hundred day moving average price of $3.02. The stock has a market capitalization of $640.24 million, a P/E ratio of -10.29 and a beta of 1.48.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after acquiring an additional 2,212,794 shares in the last quarter. Rhumbline Advisers increased its position in shares of Compass Therapeutics by 22.8% during the third quarter. Rhumbline Advisers now owns 139,313 shares of the company’s stock valued at $488,000 after purchasing an additional 25,826 shares during the period. Profund Advisors LLC acquired a new position in shares of Compass Therapeutics in the third quarter valued at $58,000. Alps Advisors Inc. raised its stake in shares of Compass Therapeutics by 11.3% in the third quarter. Alps Advisors Inc. now owns 83,007 shares of the company’s stock valued at $291,000 after purchasing an additional 8,410 shares in the last quarter. Finally, Welch & Forbes LLC bought a new position in Compass Therapeutics in the third quarter worth $52,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.